{"id":"preservative-free-tafluprost","safety":{"commonSideEffects":[{"rate":"20-50","effect":"Conjunctival hyperemia"},{"rate":"10-30","effect":"Eye irritation/discomfort"},{"rate":"5-15","effect":"Increased iris pigmentation"},{"rate":"5-15","effect":"Eyelash growth (hypertrichosis)"},{"rate":"5-10","effect":"Periocular skin darkening"}]},"_chembl":{"chemblId":"CHEMBL1963683","moleculeType":"Small molecule","molecularWeight":"452.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tafluprost mimics the action of prostaglandin F by activating FP receptors on the ciliary muscle bundle and trabecular meshwork. This activation enhances drainage of aqueous humor through the unconventional (uveoscleral) pathway, leading to decreased intraocular pressure. The preservative-free formulation aims to reduce ocular surface irritation and improve tolerability in patients requiring chronic topical therapy.","oneSentence":"Tafluprost is a prostaglandin F analog that binds to the prostaglandin F (FP) receptor to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:03.969Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT03822559","phase":"PHASE3","title":"A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2019-01-20","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":219},{"nctId":"NCT04828057","phase":"","title":"Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting","status":"COMPLETED","sponsor":"Santen Pharmaceutical (Taiwan) Co., LTD","startDate":"2021-09-01","conditions":"Ocular Surface Disease, Primary Open Angle Glaucoma","enrollment":50},{"nctId":"NCT04673604","phase":"NA","title":"From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2018-05-06","conditions":"Glaucoma, Ocular Surface Disease","enrollment":42},{"nctId":"NCT03612817","phase":"PHASE4","title":"Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2017-01","conditions":"Glaucoma, Open-Angle","enrollment":42},{"nctId":"NCT02802137","phase":"PHASE4","title":"24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2015-03","conditions":"Glaucoma, Ocular Surface Disease","enrollment":43},{"nctId":"NCT04654611","phase":"PHASE4","title":"Tafluprost Preservative Free Switch Study","status":"COMPLETED","sponsor":"Tun Hussein Onn National Eye Hospital","startDate":"2019-02-01","conditions":"Glaucoma, Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":28},{"nctId":"NCT04455126","phase":"PHASE2, PHASE3","title":"Preservative-free Tafluprost Eye Drops in Newly Diagnosed Patients With Glaucoma","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2018-04-01","conditions":"Glaucoma","enrollment":30},{"nctId":"NCT01254604","phase":"PHASE3","title":"Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-12-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":190},{"nctId":"NCT02102750","phase":"PHASE1","title":"A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2014-06","conditions":"Glaucoma, Ocular Hypertension","enrollment":17},{"nctId":"NCT03204487","phase":"PHASE4","title":"A Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost on Tear Film Thickness","status":"COMPLETED","sponsor":"Ordination Dr. Hommer","startDate":"2016-05-10","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":30},{"nctId":"NCT01026831","phase":"PHASE3","title":"Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-01-06","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":643},{"nctId":"NCT03104621","phase":"PHASE4","title":"Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients","status":"COMPLETED","sponsor":"Gangnam Severance Hospital","startDate":"2013-03","conditions":"Primary Open-angle Glaucoma","enrollment":20},{"nctId":"NCT02471105","phase":"PHASE4","title":"Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml","status":"UNKNOWN","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2015-09","conditions":"Ocular Hypertension, Glaucoma","enrollment":67},{"nctId":"NCT01979913","phase":"PHASE4","title":"An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More","status":"COMPLETED","sponsor":"Dr. Anton Hommer","startDate":"2013-10","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":16},{"nctId":"NCT01369771","phase":"PHASE4","title":"The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma","status":"COMPLETED","sponsor":"FinnMedi Oy","startDate":"2010-08","conditions":"Ocular Hypertension, Open-Angle Glaucoma","enrollment":30},{"nctId":"NCT01087671","phase":"PHASE3","title":"Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2010-04","conditions":"Ocular Hypertension, Open-Angle Glaucoma","enrollment":185},{"nctId":"NCT01162603","phase":"PHASE4","title":"Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)","status":"COMPLETED","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2011-03","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":40},{"nctId":"NCT01292460","phase":"PHASE3","title":"Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2011-02","conditions":"Ocular Hypertension, Open-angle Glaucoma","enrollment":600},{"nctId":"NCT01434888","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2011-09","conditions":"Healthy Volunteers","enrollment":15},{"nctId":"NCT01306461","phase":"PHASE3","title":"Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2011-03","conditions":"Ocular Hypertension, Open-angle Glaucoma","enrollment":401},{"nctId":"NCT00596791","phase":"PHASE3","title":"Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2008-01","conditions":"Ocular Hypertension, Open-Angle Glaucoma","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":68,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MK2452"],"phase":"phase_3","status":"active","brandName":"Preservative-Free Tafluprost","genericName":"Preservative-Free Tafluprost","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tafluprost is a prostaglandin F analog that binds to the prostaglandin F (FP) receptor to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}